HRTX News and Press, Heron Therapeutics Inc. From 03/11/24

2024-03-11 17:35:46 ET More on Heron Therapeutics Heron Therapeutics Is Out Of Survival Mode Upcoming FDA Decision: Heron Therapeutics' ZYNRELEF SNDA Heron Therapeutics Gets Back On Track Heron Therapeutics rises on securing label expansion for pain therapy ...

2024-03-11 17:35:46 ET Major earnings expected after the bell on Tuesday include: Clover Health Investments, Corp. ( CLOV ) SurgePays ( SURG ) Heron Therapeutics ( HRTX ) Qifu Technology ( QFIN ) Veritone ( VERI ) Read the full article on Se...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 PR Newswire SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announc...

2024-02-17 01:54:45 ET Summary Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the partnership with CrossLink could help acceler...

2024-01-24 09:37:29 ET A California-based %Biotech company is turning heads on Wednesday morning after it was announced that the company received FDA approval for the supplemental new drug application for %Zynrelef to include additional orthopedic and soft tissue procedures, accordi...

2024-01-24 06:28:18 ET Heron Therapeutics ( NASDAQ: HRTX ) shares rose over 7% premarket on Wednesday after the U.S Food and Drug Administration approved label expansion for the biotechnology company's postoperative pain management solution, Zynrelef (bupivacaine and meloxic...

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures PR Newswire – Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually – SAN DI...

2024-01-22 06:30:00 ET Company: Heron Therapeutics, Inc. (HRTX) SA Analyst Rating for HRTX: " Buy " SA Quant rating: " Strong Buy ". Seeking FDA Approval for greatly expanded use of ZYNRELEF for post-operative pain management in soft tissue and orthopaedic su...

2024-01-08 06:45:18 ET More on Heron Therapeutics Heron Therapeutics Gets Back On Track Why Heron Therapeutics Is A Compelling Buy Into 2024 Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript Biggest stock movers today: Boeing, Harpoon Therapeut...